Low Protein Brown Rice for Preventing Progression of CKD and DKD to End Stage Renal Failure
DOI:
https://doi.org/10.17140/DROJ-4-e012Abstract
Chronic kidney disease (CKD) is pervasive into aging society, affecting permanent implications on patients’ life. Approximately
10% of the global population has CKD, and millions die each year. The prevalence of CKD was high in Latin America, Europe,
East Asia and the Middle East, where approximately 12% of the population has CKD.1 Diabetic kidney disease (DKD) or diabetic
nephropathy (DN) is a part of CKD when the patients have diabetes.2 Both CKD and DKD may progressively fall from a normal
estimated glomerular filtration rate (eGFR >90 ml/min/1.73 m2) to less than 15, at which point the patient becomes end-stage
kidney disease (ESKD). The status of DKD could be estimated by measuring the amount of urinary protein and the serum creatinine,
which can be used to calculate the eGFR. Progression rate of CKD/DKD is recently reported by Warren et al3 who classified 15,517 participants in the communitybased Atherosclerosis Risk in Communities (ARIC) study by diabetes status. They quantified eGFR trajectories at four visits over 26 years. Adjusted mean eGFR decline over the full study period among participants without diabetes was − 1.4 ml/min/1.73 m2/ year, with undiagnosed diabetes was − 1.8 ml/min/year, and with diagnosed diabetes was − 2.5 ml/min/year.
References
World Health Organization 2016. Global report on diabetes. ISBN 978 92 4 156525 7 (NLM classification WK 810).
Diabetes Resource Guide Japan. Revision of stage classification for DKD. Website. www://dm-rg.net/news/2014/01/014349. html. Accessed, 2017.
Bethany Warren, Casey M. Rebholz, Yingying Sang, et al. Diabetes and trajectories of estimated glomerular filtration rate: A prospective cohort analysis of the atherosclerosis risk in communities study. Diabetes Care. 2018; 41 (8): 1646-1653. doi: 10.2337/dc18-0277
Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and American college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015; 21: 1-87. doi: 10.4158/EP15672.GL
The Management of Type 2 Diabetes Mellitus in Primary Care Work Group. VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care. Version 5.0. Website: https://www.healthquality.va.gov/guidelines/CD/diabetes/ VADoDDMCPGFinal508.pdf. Accessed, 2017.
Ueki K, Sasako T, Kato M, et al. Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): A multicenter, open-label, randomized, parallel-group trial. BMJ Open Diabetes Res Care. 2016; 4(1): e000123. doi: 10.1136/bmjdrc-2015-000123
J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): An open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5(12): 951-964. doi: 10.1016/S2213-8587(17)30327-3
Japan Preventive Association of Life-style related Disease. Number of hemodialysis patients. Website. www.seikatsusyukanbyo.com/statistics/2016/009096.php. Accessed, 2017.
Watanabe S. Low-protein diet for the prevention of renal failure. Proc Jpn Acad Ser B Phys Biol Sci. 2017; 93(1): 1-9. doi: 10.2183/pjab.93.001
Watanabe S, Noburu M, Yasunari M, Ideura T. A cross-sectional study on the effects of long term very low protein diets in patients with chronic kidney disease: Surum and urine DEXA and amino acid profiles. Anti-Aging Med. 2010; 7(2): 7-13. doi: 10.3793/jaam.7.7
Mizuno S. A secondary analysis of Ideura data of low protein diet practice for progressive chronic kidney disease patients. Clin Funct Nutriol. 2009; 1(5): 242-245.
Klahr S, Levy AB, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-884. doi: 10.1056/NEJM199403313301301
Watanabe S. Reevaluation of modification of diet in renal disease (MDRD study. Clin Funct Nutriol. 2009; 1(5): 238-241. Submit your article to this journal | https://openventio.org/submit-manuscript/
Yamagata K, Ideura T, Watanabe S. Tripartite: Low protein diet therapy for renal failure. Clin Funct Nutriol. 2009; 1(5): 230-236.
Watanabe S, Mizuno S, Hirakawa A. Effects of brown rice on obesity: GENKI Study I (Cross sectional epidemiological study). J Obesity Metab Dis. 2018. doi: 10.17756/jocd.2018-013
Watanabe S. Population-Based Strategy for Preventing Diabetes and its Complications. Diabetes Res Open J. 2018; 4(1): e1-e4. doi: 10.17140/DROJ-4-e011
Wakino S. Chronic kidney disease and low protein diets: Importance of the mTOR system. Clin Funct Nutriol. 2009; 1(3): 18-22.
Takei N, Watanabe N, Nakajo M. Low-protein rice (LPR) product: Processing method and product safety. Adv Food Technol Nutr Sci Open J. 2017; 3(1): 33-41. doi: 10.17140/AFTNSOJ-3-142
Watanabe S, Hirakawa A, Takei N, et al. Medical rice: A new wax-free brown rice and its protein reduced rice. Adv Food Technol Nutr Sci Open J. (in press)
David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014; 505: 559-563. doi: 10.1038/nature12820
Marlinez I, Lattimer JM, Hubach KL, Case JA, Yang J. Gut microbiome composition is linked to whole grain-induced immunological improvements. ISME J. 2013; 7: 269-280. doi: 10.1038/ismej.2012.104
Ismail-Beigi F, Moghissi E, Kosiborod M, Inzucchi SE. Shifting paradigms in the medical management of type 2 diabetes: Reflections on recent cardiovascular outcome trials. J Gen Intern Med. 2017; 32: 1044-1051. doi: 10.1007/s11606-017-4061-7
Watanabe S, Hirakawa A, Nishijima C, et al. Food as medicine: The new concept of “medical rice”. Adv Food Technol Nutr Sci Open J. 2016; 2(2): 38-50. doi: 10.17140/AFTNSOJ-2-129
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
